Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) traded down 5.2% during mid-day trading on Monday . The stock traded as low as $25.53 and last traded at $25.60. 179,460 shares were traded during trading, a decline of 39% from the average session volume of 291,805 shares. The stock had previously closed at $27.00.
Wall Street Analyst Weigh In
Several equities analysts have recently issued reports on the stock. Wedbush assumed coverage on shares of Maze Therapeutics in a report on Tuesday, July 8th. They set an "outperform" rating and a $17.00 target price for the company. Guggenheim lifted their target price on shares of Maze Therapeutics from $19.00 to $34.00 and gave the company a "buy" rating in a report on Monday, September 15th. BTIG Research lifted their target price on shares of Maze Therapeutics from $30.00 to $37.00 and gave the company a "buy" rating in a report on Friday, September 12th. JPMorgan Chase & Co. lifted their target price on shares of Maze Therapeutics from $27.00 to $37.00 and gave the company an "overweight" rating in a report on Monday. Finally, Wall Street Zen upgraded shares of Maze Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. Two equities research analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $33.83.
Check Out Our Latest Stock Analysis on Maze Therapeutics
Maze Therapeutics Price Performance
The business's fifty day moving average is $17.06 and its two-hundred day moving average is $13.17.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.77) earnings per share for the quarter, topping analysts' consensus estimates of ($0.79) by $0.02.
Insiders Place Their Bets
In related news, Director Richard H. Scheller sold 20,744 shares of the business's stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $22.37, for a total value of $464,043.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Institutional Investors Weigh In On Maze Therapeutics
A number of large investors have recently added to or reduced their stakes in MAZE. New York State Common Retirement Fund bought a new stake in Maze Therapeutics in the 1st quarter worth approximately $25,000. CWM LLC bought a new stake in Maze Therapeutics in the 2nd quarter worth approximately $28,000. Corebridge Financial Inc. bought a new stake in Maze Therapeutics in the 1st quarter worth approximately $48,000. Legal & General Group Plc grew its position in Maze Therapeutics by 387.0% in the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company's stock worth $52,000 after purchasing an additional 3,371 shares during the period. Finally, Tower Research Capital LLC TRC grew its position in Maze Therapeutics by 452.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company's stock worth $57,000 after purchasing an additional 3,774 shares during the period.
About Maze Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
